All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

SC-560 and mofezolac isosteres as new potent COX-1 selective inhibitors with antiplatelet effect

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389030%3A_____%2F23%3A00570616" target="_blank" >RIV/61389030:_____/23:00570616 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11160/23:10470932

  • Result on the web

    <a href="https://doi.org/10.1002/ardp.202200549" target="_blank" >https://doi.org/10.1002/ardp.202200549</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1002/ardp.202200549" target="_blank" >10.1002/ardp.202200549</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    SC-560 and mofezolac isosteres as new potent COX-1 selective inhibitors with antiplatelet effect

  • Original language description

    Selective cyclooxygenase (COX)-1 inhibitors can be employed as potential cardioprotective drugs. Moreover, COX-1 plays a key role in inflammatory processes and its activity is associated with some types of cancer. In this work, we designed and synthesized a set of compounds that structurally mimic the selective COX-1 inhibitors, SC-560 and mofezolac, the central cores of which were replaced either with triazole or benzene rings. The advantage of this approach is a relatively simple synthesis in comparison with the syntheses of parent compounds. The newly synthesized compounds exhibited remarkable activity and selectivity toward COX-1 in the enzymatic in vitro assay. The most potent compound, 10a (IC50 = 3 nM for COX-1 and 850 nM for COX-2), was as active as SC-560 (IC50 = 2.4 nM for COX-1 and 470 nM for COX-2) toward COX-1 and it was even more selective. The in vitro COX-1 enzymatic activity was further confirmed in the cell-based whole-blood antiplatelet assay, where three out of four selected compounds (10a,c,d, and 3b) exerted outstanding IC50 values in the nanomolar range (9–252 nM). Moreover, docking simulations were performed to reveal key interactions within the COX-1 binding pocket. Furthermore, the toxicity of the selected compounds was tested using the normal human kidney HK-2 cell line.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    10401 - Organic chemistry

Result continuities

  • Project

    <a href="/en/project/LTC18065" target="_blank" >LTC18065: Selective COX-1 inhibition as cardioprotective therapeutical target</a><br>

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2023

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Archiv der Pharmazie

  • ISSN

    0365-6233

  • e-ISSN

    1521-4184

  • Volume of the periodical

    356

  • Issue of the periodical within the volume

    5

  • Country of publishing house

    DE - GERMANY

  • Number of pages

    12

  • Pages from-to

    e2200549

  • UT code for WoS article

    000932685300001

  • EID of the result in the Scopus database

    2-s2.0-85147937585